CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH)

Seminars in Immunopathology

Volumn 36, Issue 1, 2014, Pages 55-71

  Najjar, Sonia M ^a,b   Russo, Lucia ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Adipokines; CEACAM1; Insulin resistance; Metabolic syndrome; NASH

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; FATTY ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; BONE MARROW CELL; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; FAT INTAKE; FATTY LIVER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KUPFFER CELL; LIPID METABOLISM; LIVER CELL DAMAGE; LIVER FIBROSIS; LYMPHOCYTE FUNCTION; LYMPHOID CELL; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MICE; OBESITY; OBESITY, ABDOMINAL;

EID: 84895878340     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-013-0407-3     Document Type: Review

References (263)

1. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375(9710):181-183. doi:10.1016/S0140-6736(09)61794-3
2. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793-1801. doi:10.1172/JCI29069 (Pubitemid 44033299)
3. Ferrante AW Jr (2007) Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262(4):408-414. doi:10.1111/j.1365-2796.2007.01852.x
4. Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415-445. doi:10.1146/annurev-immunol-031210-101322
5. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6):2111-2117. doi:10.1172/JCI57132
6. Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18(3):363-374. doi:10.1038/nm.2627
7. Saltiel AR (2012) Insulin resistance in the defense against obesity. Cell Metab 15(6):798-804. doi:10.1016/j.cmet.2012.03.001
8. Odegaard JI, Chawla A (2013) Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339(6116):172-177. doi:10.1126/science.1230721
9. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM (2002) CEACAM1 regulates insulin clearance in liver. Nat Genet 30(3):270-276. doi:10.1038/ng840
10. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni RN, Kim JK, Najjar SM (2008) Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes 57(9):2296-2303. doi:10.2337/db08-0379
11. Choi SS, Diehl AM (2008) Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19(3):295-300 (Pubitemid 351653569)
12. DeFronzo RA (1988) Lilly lecture, 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes Care 37(6):667-687
13. Bergman RN, Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11(9):351-356
14. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091):87-91 (Pubitemid 23036092)
15. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409(6818):307-312. doi:10.1038/35053000 (Pubitemid 32151228)
16. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7(8):947-953. doi:10.1038/90992 (Pubitemid 32756433)
17. Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55(9):2319-2326. doi:10.1007/s00125-012- 2598-x
18. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91 (Pubitemid 23036092)
19. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factoralpha in human obesity and insulin resistance. J Clin Invest 95(5):2409-2415. doi:10.1172/JCI117936
20. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271(5249):665-668 (Pubitemid 26052915)
21. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M (2003) Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 300(3):674-678 (Pubitemid 36268889)
22. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel R, Ferrante AWJ (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808 (Pubitemid 38063703)
23. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830 (Pubitemid 38063705)
24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112(12):1796-1808. doi:10.1172/JCI19246 (Pubitemid 38063703)
25. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112(12):1821-1830. doi:10.1172/JCI19451 (Pubitemid 38063705)
26. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354(6):610-621. doi:10.1056/NEJMra052723 (Pubitemid 43209108)
27. Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219-246. doi:10.1146/annurev-physiol-021909- 135846
28. Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H (2003) Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes inmice. J Biol Chem 278(47):46654-46660. doi:10.1074/jbc.M309895200 (Pubitemid 37452242)
29. Kwon H, Pessin JE (2013) Adipokines mediate inflammation and insulin resistance. Front Endocrinol 4:71. doi:10.3389/fendo.2013.00071
30. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15(8):921-929. doi:10.1038/nm.2001
31. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332(6026):243-247. doi:10.1126/science.1201475
32. Talukdar S, da Oh Y, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, Ofrecio J, Lin M, Brenner MB, Olefsky JM (2012) Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 18(9):1407-1412. doi:10.1038/nm.2885
33. Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, Davis RJ (2013) JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 339(6116):218-222. doi:10.1126/science.1227568
34. Halberg N, Wernstedt-Asterholm I, Scherer PE (2008) The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 37(3):753-768. doi:10.1016/j.ecl.2008.07.002, x-xi
35. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548-2556. doi:10.1210/jc.2004-0395 (Pubitemid 38766330)
36. Sjoholm A, Nystrom T (2005) Endothelial inflammation in insulin resistance. Lancet 365(9459):610-612. doi:10.1016/S0140-6736(05)17912-4 (Pubitemid 40247919)
37. Lazar MA (2005) How obesity causes diabetes: not a tall tale. Science 307(5708):373-375. doi:10.1126/science.1104342 (Pubitemid 40139971)
38. Tataranni PA, Ortega E (2005) A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 54(4):917-927 (Pubitemid 40446304)
39. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J (2004) Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2960-2965 (Pubitemid 39565066)
40. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638 (Pubitemid 36459468)
41. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389(6651):610-614. doi:10.1038/39335 (Pubitemid 27446179)
42. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293(5535):1673-1677. doi:10.1126/science.1061620 (Pubitemid 32807849)
43. Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7(10):1138-1143. doi:10.1038/nm1001-1138 (Pubitemid 33010023)
44. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420(6913):333-336. doi:10.1038/nature01137 (Pubitemid 35398190)
45. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11(2):183-190. doi:10.1038/nm1166 (Pubitemid 40321354)
46. Frayn KN (2000) Visceral fat and insulin resistance - causative or correlative? Br J Nutr 83(Suppl 1):S71-S77
47. Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW (2003) Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 27(8):875-888. doi:10.1038/sj.ijo.0802326 (Pubitemid 36918608)
48. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk ML, Potts JL, Hockaday TD (1992) Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 41:264-272
49. Sykiotis GP, Papavassiliou AG (2001) Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 15:1864-1869 (Pubitemid 33022527)
50. Le Marchand-Brustel Y, Gual P, Gremeaux T, Gonzalez T, Barres R, Tanti JF (2003) Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling. Biochem Soc Trans 31:1152-1156 (Pubitemid 38030928)
51. Hotamisligil GS (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140(6):900-917. doi:10.1016/j.cell.2010.02.034
52. Kim JK (2010) Inflammation and insulin resistance: an old story with new ideas. Korean Diabetes J 34(3):137-145. doi:10.4093/kdj.2010.34.3.137
53. Le Marchand-Brustel Y, Gual P, Gremeaux T, Gonzalez T, Barres R, Tanti JF (2003) Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling. Biochem Soc Trans 31(Pt 6):1152-1156. doi:10.1042/
54. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190 (Pubitemid 40321354)
55. Lang CH, Dobrescu C, Bagby GJ (1992) Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130(1):43-52
56. Porter MH, Cutchins A, Fine JB, Bai Y, DiGirolamo M (2002) Effects of TNF-alpha on glucosemetabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Lab Clin Med 139(3):140-146 (Pubitemid 34286950)
57. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A (1993) Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268(35):26055-26058
58. Hutley L, Prins JB (2005) Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 330(6):280-289 (Pubitemid 41831898)
59. Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML (1999) Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99(4):546-551 (Pubitemid 29061871)
60. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87(5):2084-2089 (Pubitemid 34521492)
61. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56(4):1010-1013. doi:10.2337/db06-1656 (Pubitemid 46525079)
62. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278(16):13740-13746. doi:10.1074/jbc.M210689200 (Pubitemid 36799910)
63. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, Jowett JB, Watt MJ, Jansson JO, Bruce CR, Febbraio MA (2010) Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53(11):2431-2441. doi:10.1007/s00125-010-1865-y
64. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8(1):75-79. doi:10.1038/nm0102-75 (Pubitemid 34101732)
65. El-Kadre LJ, Tinoco AC (2013) Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care 16(5):564-568. doi :10.1097/MCO.0b013e32836410e6
66. Jansson JO, Wallenius K, Wernstedt I, Ohlsson C, Dickson SL, Wallenius V (2003) On the site and mechanismof action of the antiobesity effects of interleukin-6. Growth Horm IGF Res 13 Suppl A: S28-32
67. Franckhauser S, Elias I, Rotter Sopasakis V, Ferre T, Nagaev I, Andersson CX, Agudo J, Ruberte J, Bosch F, Smith U (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51(7):1306-1316. doi:10.1007/s00125-008-0998-8
68. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505):425-432. doi:10.1038/372425a0 (Pubitemid 24365442)
69. Mantzoros CS (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130(8):671-680
70. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI (1998) Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394(6696):897-901. doi:10.1038/29795 (Pubitemid 28410912)
71. Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. J Immunol 174(6):3137-3142 (Pubitemid 40354011)
72. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F (2005) Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42(6):1339-1348. doi:10.1002/hep.20965 (Pubitemid 43260036)
73. Gan L, Guo K, Cremona ML, McGraw TE, Leibel RL, Zhang Y (2012) TNF-alpha up-regulates protein level and cell surface expression of the leptin receptor by stimulating its export via a PKC-dependent mechanism. Endocrinology 153(12):5821-5833. doi:10.1210/en.2012-1510
74. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116(7):1784-1792. doi:10.1172/JCI29126 (Pubitemid 44033298)
75. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288-1295. doi:10.1038/nm788 (Pubitemid 35373562)
76. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2):179-188. doi:10.1001/jama.2009.976
77. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9):2094-2099 (Pubitemid 33643677)
78. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions ofmacrophages. Blood 96(5):1723-1732 (Pubitemid 30661055)
79. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117(2):375-386. doi: 10.1172/JCI29709 (Pubitemid 46203966)
80. Wilk S, Jenke A, Stehr J, Yang CA, Bauer S, Goldner K, Kotsch K, Volk HD, Poller W, Schultheiss HP, Skurk C, Scheibenbogen C (2013) Adiponectin modulates NK-cell function. Eur J Immunol 43(4):1024-1033. doi:10.1002/eji.201242382
81. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8(7):731-737. doi:10.1038/nm724 (Pubitemid 34778727)
82. Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288(5):R1220-R1225. doi:10.1152/ajpregu.00397.2004 (Pubitemid 40593705)
83. Bugianesi E, McCullough AJ, Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42(5):987-1000. doi:10.1002/hep.20920 (Pubitemid 43112663)
84. Vettor R, Milan G, Rossato M, Federspil G (2005) Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22(Suppl 2):3-10. doi:10.1111/j.1365-2036.2005.02587.x (Pubitemid 41564373)
85. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109(17):2046-2049. doi:10.1161/01.CIR.0000127953.98131.ED (Pubitemid 38620209)
86. Tilg H, Wolf AM (2005) Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther 9(2):245-251. doi:10.1517/14728222.9.2.245 (Pubitemid 40613866)
87. Boden G (2006) Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 6:177-181
88. Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486
89. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW (2000) Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest 30:45-52 (Pubitemid 30071856)
90. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, Balkau B (1997) The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101-1106 (Pubitemid 27381974)
91. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403. doi:10.1056/NEJMoa012512 (Pubitemid 34437694)
92. Ostman J, Arner P, Engfeldt P, Kager L (1979) Regional differences in the control of lipolysis in human adipose tissue. Metabolism 28:1198-1205 (Pubitemid 10181708)
93. Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23(2):201-229 (Pubitemid 34299024)
94. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl 1):S43-S50
95. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10
96. Bergman RN, Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356
97. Rebrin K, Steil GM, Getty L, Bergman RN (1995) Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 44(9):1038-1045
98. Bays H, Mandarino L, DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, Review (Pubitemid 38269844)
99. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, Bergman RN (2005) Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288(2):E454-E461. doi:10.1152/ajpendo.00203.2004 (Pubitemid 40110656)
100. Williamson JR, Kreisberg RA, Felts PW (1966) Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A 56:247-254
101. Massillon D, Barzilai N, Hawkins M, Prus-Wertheimer D, Rossetti L (1997) Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 46(1):153-157 (Pubitemid 27009965)
102. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW (1997) Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 46:1768-1774 (Pubitemid 27456409)
103. Sidossis LS, Mittendorfer B, Walser E, Chinkes D, Wolfe RR (1998) Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am J Physiol 275:E798-E805
104. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M (2002) FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 283(1):E12-E19. doi:10.1152/ajpendo.00429.2001 (Pubitemid 34686662)
105. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, Bergman RN (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49:2116-2125
106. Randle PJ, Hales CN, Garland PB, Newsholm EA (1963) The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
107. Freedland ES (2004) Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond) 1:12
108. Freedland ES (2004) Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. NutrMetab (Lond) 1(1):12. doi:10.1186/1743-7075-1-12
109. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB (2003) Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes 52:1935-1942 (Pubitemid 36919784)
110. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM (2005) JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280(42):35361-35371. doi:10.1074/jbc.M504611200 (Pubitemid 41532725)
111. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl 1):S99-S112. doi:10.1002/hep.20973
112. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332(6037):1519-1523. doi:10.1126/science. 1204265
113. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40(Suppl 1):S17-S29. doi:10.1097/01.mcg.0000168645.86658.22
114. Harrison SA, Kadakia S, Lang KA, Schenker S (2002) Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 97(11):2714-2724. doi:10.1111/j.1572-0241.2002.07069.x (Pubitemid 35265419)
115. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11(1):74-80 (Pubitemid 20075105)
116. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J (2003) Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38(2):420-427. doi:10.1053/jhep.2003.50320 (Pubitemid 36919863)
117. Neuschwander-Tetri BA (2005) Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330(6):326-335
118. Brunt EM (2005) Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 22:330-338
119. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313-1321. doi:10.1002/hep.20701 (Pubitemid 40770284)
120. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14(2):72-81. doi:10.1016/j.molmed.2007.12.003
121. Torres DM, Williams CD, Harrison SA (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10(8):837-858. doi:10.1016/j.cgh.2012.03.011
122. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845
123. Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5):663-678
124. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4):917-923. doi:10.1053/jhep.2003.50161 (Pubitemid 36397405)
125. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113-121 (Pubitemid 41002048)
126. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81
127. Green RM (2003) NASH-hepatic metabolism and not simply the metabolic syndrome. Hepatology 38(1):14-17. doi:10.1053/jhep.2003.50325
128. Erickson SK (2009) Nonalcoholic fatty liver disease. J Lipid Res 50(Suppl):S412-S416. doi:10.1194/jlr.R800089-JLR200
129. Fisher EA, Ginsberg HN (2002) Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277(20):17377-17380 (Pubitemid 34967535)
130. Haeusler RA, Accili D (2008) The double life of Irs. Cell Metab 8(1):7-9. doi:10.1016/j.cmet.2008.06.010 (Pubitemid 351859234)
131. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7(2):95-96. doi:10.1016/j.cmet.2007.12.009 (Pubitemid 351168559)
132. Takahashi Y, Fukusato T (2010) Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. World J Gastroenterol 16(42):5280-5285
133. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T (2012) Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 47(5):586-595. doi:10.1007/s00535-012-0533-z
134. Knobler H, Schattner A (1999) Non-alcoholic steatohepatitis. Lancet 354(9186):1298-1299. doi:10.1016/S0140-6736(05)76068-2
135. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86(11):839-848 (Pubitemid 39602764)
136. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C (2007) Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 18(3):184-195. doi:10.1016/j.jnutbio.2006.12.006 (Pubitemid 46216810)
137. Green RM (2003) NASH-hepatic metabolism and not simply the metabolic syndrome. Hepatology 38(1):14-17
138. Abdelmalek MF, Diehl AM (2007) Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 91:1125-1149, ix (Pubitemid 47625434)
139. Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, Arakawa T, Hato F, Kawada N (2007) Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 170:967-980 (Pubitemid 47339365)
140. Leclercq IA, Farrell GC, Schriemer R, Robertson GR (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37(2):206-213 (Pubitemid 34833082)
141. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H (2005) Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25(6):2498-2510. doi:10.1128/MCB.25.6.2498-2510.2005 (Pubitemid 40354642)
142. Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, Hashinaga T, Wada N, Yamada K (2007) Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 56:470-475 (Pubitemid 46427843)
143. Okumura K, Ikejima K, Kon K, Abe W, Yamashina S, Enomoto N, Takei Y, Sato N (2006) Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK-A(y) mice. Hepatol Res 36(3):217-228. doi:10.1016/j.hepres.2006.07. 009 (Pubitemid 44575929)
144. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A (2006) A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169(3):846-860 (Pubitemid 44411952)
145. Rinella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40:47-51 (Pubitemid 38064712)
146. Lieber CS (2004) CYP2E1: from ASH to NASH. Hepatol Res 28:1-11
147. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46(5):1392-1403. doi:10.1002/hep.21874 (Pubitemid 350155521)
148. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, Sela BA (2005) Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 45(5):1012-1018. doi:10.1161/01.HYP.0000164570.20420.67 (Pubitemid 40628952)
149. Basaranoglu M, Basaranoglu G, Sabuncu T, Senturk H (2013) Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 19(8):1166-1172. doi:10.3748/wjg.v19.i8.1166
150. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, Conca P, Contaldo F, Pasanisi F (2005) Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 49(5):289-295. doi:10.1159/000087295 (Pubitemid 41291550)
151. Tarantino G, Caputi A (2011) JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol 17(33):3785-3794. doi:10.3748/wjg.v17.i33.3785
152. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P (2010) Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 5(10):e13577. doi:10.1371/journal.pone.0013577
153. Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, Chiesa C (2006) Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol 154(5):691-697. doi:10.1530/eje.1.02138 (Pubitemid 43810855)
154. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF (2005) "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1(5):309-322. doi:10.1016/j.cmet.2005.04.002 (Pubitemid 43977168)
155. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM (1999) Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 274:5692-5700 (Pubitemid 29109222)
156. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191-198 (Pubitemid 40321355)
157. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, Morales A (1997) GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 273:G7-G17
158. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G (2005) NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129:1663-1674 (Pubitemid 41597405)
159. Day CP (2006) From fat to inflammation. Gastroenterology 130:207-210
160. McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I (2004) Mechanisms of non-alcoholic steatohepatitis. Alcohol 34:67-79 (Pubitemid 40163990)
161. Basseri S, Austin RC (2008) ER stress and lipogenesis: a slippery slope toward hepatic steatosis. Dev Cell 15(6):795-796. doi:10.1016/j.devcel.2008.11. 013
162. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, Clark R, Miao H, Hassler JR, Fornek J, Katze MG, Hussain MM, Song B, Swathirajan J, Wang J, Yau GD, Kaufman RJ (2008) UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell 15(6):829-840. doi:10.1016/j.devcel.2008.10.015
163. Ji C (2008) Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J Gastroenterol Hepatol 23(Suppl 1):S16-S24. doi:10.1111/j.1440-1746.2007.05276.x
164. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ (2006) JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1):163-172. doi:10.1002/hep.20999 (Pubitemid 43733603)
165. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333-336 (Pubitemid 35398190)
166. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ (2009) Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136(2):249-260. doi:10.1016/j.cell.2008.11.017
167. Dong Z, Wei H, Sun R, Tian Z (2007) The roles of innate immune cells in liver injury and regeneration. Cell Mol Immunol 4(4):241-252
168. Diehl AM (2002) Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 282(1):G1-G5. doi:10.1152/ajpgi.00384.2001
169. Tacke F (2012) Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair 5 Suppl 1:S27. doi:10.1186/1755-1536-5-S1-S27
170. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7(6):496-507. doi:10.1016/j.cmet.2008.04.003 (Pubitemid 351729205)
171. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake K, Tobe K, Arai H, Kadowaki T, Nagai R (2012) Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 15(4):518-533. doi:10.1016/j.cmet.2012.01.023
172. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E (2012) Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond) 122(11):545-553. doi:10.1042/CS20110366
173. Tilg H, Moschen AR, Kaser A (2009) Obesity and the microbiota. Gastroenterology 136(5):1476-1483. doi:10.1053/j.gastro.2009.03.030
174. Pessayre D (2007) Role of mitochondria in non-alcoholic fatty liver disease. JGastroenterolHepatol 22(Suppl 1):S20-S27. doi:10.1111/j.1440-1746. 2006.04640.x
175. Videla LA, Rodrigo R, Araya J, Poniachik J (2006) Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 12(12):555-558. doi:10.1016/j.molmed.2006.10.001 (Pubitemid 44780196)
176. Fujii H, Kawada N (2012) Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 47(3):215-225. doi:10.1007/s00535-012-0527-x
177. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54(7):987-993. doi:10.1136/gut.2004.057968 (Pubitemid 40873914)
178. Claria J (2012) Natural killer cell recognition and killing of activated hepatic stellate cells. Gut 61(6):792-793. doi:10.1136/gutjnl-2011-301968
179. Hidaka T, Akada S, Teranishi A, Morikawa H, Sato S, Yoshida Y, Yajima A, Yaegashi N, Okamura K, Saito S (2003) Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function. Cancer Sci 94(9):814-820 (Pubitemid 37258781)
180. Niemeyer M, Darmoise A, Mollenkopf HJ, Hahnke K, Hurwitz R, Besra GS, Schaible UE, Kaufmann SH (2008) Natural killer T-cell characterization through gene expression profiling: an account of versatility bridging T helper type 1 (Th1), Th2 and Th17 immune responses. Immunology 123(1):45-56. doi:10.1111/j.1365-2567.2007.02701.x (Pubitemid 350255998)
181. Maher JJ, Leon P, Ryan JC (2008) Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48(2):670-678. doi:10.1002/hep.22399
182. Kremer M, Hines IN (2008) Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J Gastroenterol 14(3):487-488 (Pubitemid 351320862)
183. Xu CF, Yu CH, Li YM, Xu L, Du J, Shen Z (2007) Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease. World J Gastroenterol 13(33):4504-4508 (Pubitemid 47412416)
184. Li Z, Soloski MJ, Diehl AM (2005) Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42:880-885 (Pubitemid 41401126)
185. Elinav E, Pappo O, Sklair-Levy M, Margalit M, Shibolet O, Gomori M, Alper R, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y (2006) Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J Pathol 209:121-128
186. Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T (2009) Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 21(6):673-680. doi:10.1097/MEG.0b013e32831bc3d6
187. Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, Witek RP, Choi SS, Guy CD, Fearing CM, Teaberry V, Pereira FE, Adams DH, Diehl AM (2010) Accumulation of natural killer Tcells in progressive nonalcoholic fatty liver disease. Hepatology 51(6):1998-2007. doi:10.1002/hep.23599
188. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J (2008) Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48(2):449-457. doi:10.1002/hep.22350
189. Tilg H, Hotamisligil GS (2006) Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131:934-945 (Pubitemid 44307061)
190. Tilg H, Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343(20):1467-1476. doi:10.1056/NEJM200011163432007
191. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350 (Pubitemid 36152533)
192. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J (2004) Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40(1):46-54. doi:10.1002/hep.20280 (Pubitemid 38868922)
193. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons- Romero F (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-1163 (Pubitemid 33096588)
194. Manco M, Marcellini M, Giannone G, Nobili V (2007) Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127:954-960
195. Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, Lesmana LA (2009) Diagnostic value of a group of biochemical markers of liver fibrosis in patients with nonalcoholic steatohepatitis. J Dig Dis 10(3):201-206. doi:10.1111/j.1751-2980.2009.00386.x
196. Baranova A, Schlauch K, Elariny H, Jarrar M, Bennett C, Nugent C, Gowder SJ, Younoszai Z, Collantes R, Chandhoke V, Younossi ZM (2007) Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 17(8):1111-1118 (Pubitemid 350042936)
197. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103(6):1372-1379. doi:10.1111/j.1572-0241. 2007.01774.x (Pubitemid 351813900)
198. Bhogal RK, Bona CA (2005) B cells: no longer bystanders in liver fibrosis. J Clin Invest 115(11):2962-2965. doi:10.1172/JCI26845 (Pubitemid 41567558)
199. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A (2005) Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115(11):3072-3082. doi:10.1172/JCI24798 (Pubitemid 41567572)
200. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274(5291):1379-1383 (Pubitemid 26391463)
201. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B (2004) IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 1(3):205-211
202. Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Fujii H, Okanoue T, Yoshikawa T (2010) Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest 90(8):1169-1178. doi:10.1038/labinvest.2010.75
203. Diehl AM, Li ZP, Lin HZ, Yang SQ (2005) Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54(2):303-306. doi:10.1136/gut.2003.024935 (Pubitemid 40139250)
204. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J (2002) Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36(2):403-409. doi:10.1053/jhep.2002.34738 (Pubitemid 34810360)
205. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122(5):1399-1410 (Pubitemid 34465182)
206. Potter JJ, Rennie-Tankesley L, Mezey E (2003) Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration. J Hepatol 38(3):281-288 (Pubitemid 36286540)
207. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD (2004) Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 41(6):943-949. doi:10.1016/j.jhep.2004.08.020 (Pubitemid 39575661)
208. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV (2003) Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 98:2771-2776 (Pubitemid 38020122)
209. Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T (2000) Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 33(1):33-37 (Pubitemid 30418931)
210. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Cassader M, Durazzo M, Rizzetto M, Pagano G (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100(11):2438-2446. doi:10.1111/j.1572-0241.2005.00297.x
211. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54(1):117-121. doi:10.1136/gut.2003.037010 (Pubitemid 40007229)
212. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285(3):E527-E533. doi:10.1152/ajpendo.00110.2003 (Pubitemid 37010830)
213. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Mohlig M, Pfeiffer AF, Luft FC, Sharma AM (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52(4):942-947 (Pubitemid 36384264)
214. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280(5):E745-E751
215. Moschen AR, Wieser V, Tilg H (2012) Adiponectin: key player in the adipose tissue-liver crosstalk. Curr Med Chem 19(32):5467-5473
216. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112(1):91-100. doi:10.1172/JCI17797 (Pubitemid 38056380)
217. Ueno T, Nakamura A, Nakayama H, Otabe S, Yuan X, Fukutani T, Iwamoto H, Nakamura T, Koga H, Torimura T, Sata M, Yamada K (2011) Exp Ther Med. Exp Ther Med 2(6):1035-1040. doi:10.3892/etm.2011.348
218. Öbrink B (1997) CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol 9(5):616-626
219. Najjar SM, Accili D, Philippe N, Jernberg J, Margolis R, Taylor SI (1993) pp 120/ecto-ATPase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. J Biol Chem 268:1201-1206 (Pubitemid 23019761)
220. Nagaishi T, Iijima H, Nakajima A, Chen D, Blumberg RS (2006) Role of CEACAM1 as a regulator of T cells. Ann N Y Acad Sci 1072:155-175. doi:10.1196/annals.1326.004 (Pubitemid 44448450)
221. Gray-Owen SD, Blumberg RS (2006) CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 6:433-446
222. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, Yagel S, Mandelboim O (2002) Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 110(7):943-953. doi:10.1172/JCI15643
223. Chen CJ, Shively JE (2004) The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor. J Immunol 172:3544-3552
224. Kammerer R, Hahn S, Singer BB, Luo JS, von Kleist S (1998) Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation. Eur J Immunol 28(11):3664-3674. doi:10.1002/(SICI)1521- 4141(199811)28:11〈3664::AID-IMMU3664〉3.0.CO;2-D (Pubitemid 28510777)
225. Nakajima A, Iijima H, Neurath MF, Nagaishi T, Nieuwenhuis EE, Raychowdhury R, Glickman J, Blau DM, Russell S, Holmes KV, Blumberg RS (2002) Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T lymphocyte function. J Immunol 168(3):1028-1035 (Pubitemid 34094465)
226. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O (2002) CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 168(6):2803-2810 (Pubitemid 34211659)
227. Iijima H, Neurath MF, Nagaishi T, Glickman JN, Nieuwenhuis EE, Nakajima A, Chen D, Fuss IJ, Utku N, Lewicki DN, Becker C, Gallagher TM, Holmes KV, Blumberg RS (2004) Specific regulation of T helper cell 1-mediatedmurine colitis by CEACAM1. J Exp Med 199(4):471-482. doi:10.1084/jem.20030437 (Pubitemid 38233831)
228. Hosomi S, Chen Z, Baker K, Chen L, Huang YH, Olszak T, Zeissig S, Wang JH, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS (2013) CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling. Eur J Immunol. doi:10.1002/eji.201242676
229. Veillette A, Latour S, Davidson D (2002) Negative regulation of immunoreceptor signaling. Annu Rev Immunol 20:669-707. doi:10.1146/annurev. immunol.20.081501.130710 (Pubitemid 34293437)
230. Abraham RT, Weiss A (2004) Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol 4(4):301-308. doi:10.1038/nri1330 (Pubitemid 38478665)
231. Coutelier JP, Godfraind C, Dveksler GS, Wysocka M, Cardellichio CB, Noel H, Holmes KV (1994) B lymphocyte and macrophage expression of carcinoembryonic antigen-related adhesion molecules that serve as receptors formurine coronavirus. Eur J Immunol 24(6):1383-1390. doi:10.1002/eji.1830240622 (Pubitemid 24169523)
232. Greicius G, Severinson E, Beauchemin N, Obrink B, Singer BB (2003) CEACAM1 is a potent regulator of B cell receptor complex-induced activation. J Leukoc Biol 74(1):126-134 (Pubitemid 38040445)
233. Chen T, Zimmermann W, Parker J, Chen I, Maeda A, Bolland S (2001) Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals. J Leukoc Biol 70(2):335-340 (Pubitemid 32751527)
234. Lobo EO, Zhang Z, Shively JE (2009) Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependentmanner. J Leukoc Biol 86(2):205-218. doi:10.1189/jlb.0109037
235. Kammerer R, Stober D, Singer BB, Obrink B, Reimann J (2001) Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J Immunol 166(11):6537-6544 (Pubitemid 32467192)
236. Lu R, Pan H, Shively JE (2012) CEACAM1 negatively regulates IL-1beta production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog 8(4):e1002597. doi:10.1371/journal.ppat. 1002597
237. Boulton IC, Gray-Owen SD (2002) Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 3(3):229-236. doi:10.1038/ni769 (Pubitemid 34213424)
238. Pan H, Shively JE (2010) Carcinoembryonic antigen-related cell adhesion molecule-1 regulates granulopoiesis by inhibition of granulocyte colony-stimulating factor receptor. Immunity 33(4):620-631. doi:10.1016/j. immuni.2010.10.009
239. Carpentier JL (1994) Insulin receptor internalization: molecular mechanisms and physiopathological implications. Diabetologia 37(Suppl 2):S117-S124
240. Najjar SM (2002) Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 13:240-245
241. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI (1995) Insulin-stimulated phosphorylation of recombinant pp 120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 34:9341-9349
242. Li Calzi S, Choice CV, Najjar SM (1997) Differential effect of pp 120 on insulin endocytosis by two variant insulin receptor isoforms. Am J Physiol 273:E801-E808
243. Formisano P, Najjar SM, Gross CN, Philippe N, Oriente F, Kern-Buell CL, Accili D, Gorden P (1995) Receptor-mediated internalization of insulin. Potential role of pp 120/HA4, a substrate of the insulin receptor kinase. J Biol Chem 270(41):24073-24077
244. Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, Ruch RJ, Smith S, Lin SH, Beauchemin N, Oyarce AM (2005) Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2(1):43-53. doi:10.1016/j.cmet.2005.06.001 (Pubitemid 43239824)
245. Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, White MF, Copps KD, Volpi E, Fujita S, Butler PC (2012) Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 61(9):2269-2279. doi:10.2337/db11-1462
246. Ward GM, Walters JM, Aitken PM, Best JD, Alford FP (1990) Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity. Diabetes Care 39(4):501-507 (Pubitemid 20111435)
247. Xu E, Dubois MJ, Leung N, Charbonneau A, Turbide C, Avramoglu RK, DeMarte L, Elchebly M, Streichert T, Levy E, Beauchemin N, Marette A (2009) Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology 150:3503-3512. doi:10.1210/en.2008-1439
248. Park SY, Cho YR, Kim HJ, Hong EG, Higashimori T, Lee SJ, Goldberg IJ, Shulman GI, Najjar SM, Kim JK (2006) Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab 291(3):E517-E524. doi:10.1152/ajpendo.00077.2006 (Pubitemid 44352257)
249. Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, McInerney MF, Erickson SK, Gatto-Weis C, Najjar SM (2008) Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 135(6):2084-2095. doi:10.1053/j.gastro.2008.08.007
250. Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McLnerney MF, Erickson SK, Bourey RE, Najjar SM (2010) Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med Res Evidence 2010(2):69-78. doi:10.2147/HMER.S8902
251. Najjar SM, Ledford KJ, Abdallah SL, Paus A, Russo L, Kaw MK, Ramakrishnan SK, Muturi HT, Raphael CK, Lester SG, Heinrich G, Pierre SV, Benndorf R, Kleff V, Jaffa AA, Levy E, Vazquez G, Goldberg IJ, Beauchemin N, Scalia R, Ergun S (2013) Ceacam1 deletion causes vascular alterations in large vessels. Am J Physiol Endocrinol Metab 305(4):E519-E529. doi:10.1152/ajpendo.00266.2013
252. Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, Chen Z, Glickman J, Najjar SM, Nakajima A, Neel BG, Blumberg RS (2006) SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 25:769-781 (Pubitemid 46107284)
253. Aarsland A, Chinkes D, Wolfe RR (1996) Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J Clin Invest 98:2008-2017 (Pubitemid 26376288)
254. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356-1362
255. Syn WK, Choi SS, Diehl AM (2009) Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 13(4):565-580. doi:10.1016/j.cld.2009.07.003
256. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR (2009) The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 138(5):961-975. doi:10.1016/j.cell.2009.06.046
257. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW (2008) Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 28:1982-1988. doi:10.1161/ATVBAHA.108.169722
258. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025. doi:10.1172/JCI28898 (Pubitemid 44684486)
259. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4:185-198 (Pubitemid 44307975)
260. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123(4):1323-1330
261. Lewis JR, Mohanty SR (2010) Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55(3):560-578. doi:10.1007/s10620-009-1081-0
262. Carter-Kent C, Zein NN, Feldstein AE (2008) Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103:1036-1042 (Pubitemid 351501089)
263. Lee W (2011) The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagn Pathol 6:40. doi:10.1186/1746-1596-6-40